New research published in Science Advances today conducted by researchers at Peter MacCallum Cancer Center show a new treatment for two challenging blood cancers could potentially help more patients than originally thought.

Associate Professor Nicholas Clemons, Group Leader in the Cancer Evolution and Metastasis Program at Peter Mac, said, "Our research highlighted an additional mode of action for the treatment known as eprenetapopt opening up its potential to work in a broader group of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients.

"The treatment was initially thought to only target patients with the TP53 mutation however we believe it could be beneficial to substantially more patients."

AML is a type of blood cancer known as leukemia. It is characterized by the bone marrow producing too many immature white blood cells. This stops the marrow from being able to make normal blood cells.

Read more...